<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnosis and treatment of disseminated histoplasmosis in patients without HIV</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnosis and treatment of disseminated histoplasmosis in patients without HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnosis and treatment of disseminated histoplasmosis in patients without HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John W Baddley, MD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Histoplasmosis is a common endemic mycosis that is usually asymptomatic but occasionally results in severe illness. Histoplasmosis and its causative agent, <em>Histoplasma capsulatum</em>, are found worldwide but particularly in North and Central America. Within the United States, infection is most common in the Midwestern states located in the Ohio and Mississippi River valleys. Among the endemic mycoses, it is the most common cause for hospitalization [<a href="#rid1">1</a>]. Histoplasmosis is also a major cause of opportunistic infection in several Latin American countries [<a href="#rid2">2,3</a>].</p><p>Disseminated histoplasmosis implies extrapulmonary infection [<a href="#rid4">4</a>]. Silent hematogenous dissemination probably occurs in most persons during the acute infection before cellular immunity develops. Most patients who develop symptomatic disseminated histoplasmosis are immunosuppressed (eg, acquired immunodeficiency syndrome [AIDS], solid organ transplantation, treatment with tumor necrosis factor-alpha inhibitors) or are at the extremes of age. In addition, chronic disseminated histoplasmosis occurs uncommonly in older adults who have no known immunosuppressing conditions. (See  <a class="medical medical_review" href="/z/d/html/2455.html" rel="external">"Pathogenesis and clinical manifestations of disseminated histoplasmosis", section on 'Risk factors'</a>.)</p><p>The diagnosis of disseminated histoplasmosis requires a high index of suspicion, recognition of the common modes of presentation, and familiarity with the appropriate diagnostic tests. Treatment is highly effective, but relapse can occur. The diagnosis and treatment of disseminated histoplasmosis will be reviewed here. The pathogenesis, risk factors for dissemination, and clinical manifestations of this infection and the diagnosis and treatment of pulmonary histoplasmosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2455.html" rel="external">"Pathogenesis and clinical manifestations of disseminated histoplasmosis"</a> and  <a class="medical medical_review" href="/z/d/html/2451.html" rel="external">"Diagnosis and treatment of pulmonary histoplasmosis"</a>.)</p><p class="headingAnchor" id="H1688783114"><span class="h1">DIAGNOSIS OF DISSEMINATED HISTOPLASMOSIS</span></p><p class="headingAnchor" id="H3"><span class="h2">When to suspect the diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of disseminated histoplasmosis should be suspected in patients with risk factors for disease (eg, immunosuppression or extremes of age and risk factors for exposure) in combination with clinical manifestations that are consistent with disseminated histoplasmosis. (See  <a class="medical medical_review" href="/z/d/html/2455.html" rel="external">"Pathogenesis and clinical manifestations of disseminated histoplasmosis"</a>.)</p><p>The most common symptoms of disseminated histoplasmosis are fever, fatigue, and weight loss. Other clinical symptoms depend on the organ system involved. Physical examination, radiographic, and laboratory abnormalities that can be seen in patients with disseminated histoplasmosis include [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral lymphadenopathy, hepatomegaly, splenomegaly, skin lesions, mucosal lesions, altered mental status, and other neurologic abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anemia, leukopenia, and thrombocytopenia  (<a class="graphic graphic_picture graphicRef57613" href="/z/d/graphic/57613.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevations in serum aminotransferases, alkaline phosphatase, and/or bilirubin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Markedly elevated serum lactate dehydrogenase and ferritin values.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interstitial or reticulonodular infiltrates – Chest radiographs are abnormal in the majority of patients with disseminated histoplasmosis, usually showing diffuse interstitial or reticulonodular infiltrates  (<a class="graphic graphic_diagnosticimage graphicRef53565" href="/z/d/graphic/53565.html" rel="external">image 1</a>); mediastinal adenopathy occurs less often, and cavitation is rare [<a href="#rid6">6-8</a>]. Although diffuse infiltrates are also seen in patients with acute pulmonary histoplasmosis following a large inoculum exposure, in the absence of such an exposure history, diffuse reticulonodular infiltrates suggest disseminated disease, especially in an immunosuppressed patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cerebrospinal fluid findings of lymphocytic pleocytosis, elevated protein, and low glucose concentration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Single or multiple enhancing brain lesions on computed tomography (CT) scan or magnetic resonance imaging (MRI)  (<a class="graphic graphic_diagnosticimage graphicRef70552" href="/z/d/graphic/70552.html" rel="external">image 2</a>) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal CT scan showing enlargement of the spleen, adrenal glands, or lymph nodes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lesions in the stomach, small intestines, or colon found on gastrointestinal endoscopy.</p><p></p><p class="headingAnchor" id="H126669197"><span class="h2">Establishing the diagnosis</span><span class="headingEndMark"> — </span>Microscopic demonstration or isolation of <em>Histoplasma</em> from extrapulmonary sites provides proof of dissemination in patients with histoplasmosis. Histopathology using stains for fungi, cultures, antigen detection, tests for <em>Histoplasma</em>-specific antibodies, and PCR can all be used to help make the diagnosis [<a href="#rid10">10-12</a>]. </p><p>Rapid diagnosis is usually achieved by one of the following methods:</p><p class="bulletIndent1"><span class="glyph">●</span>Antigen detection. (See <a class="local">'Antigen testing'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cytologic and/or histopathologic examination of tissue samples, respiratory secretions, or body fluids. (See <a class="local">'Cytology and histopathology'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wright's stain of blood smears  (<a class="graphic graphic_picture graphicRef57613" href="/z/d/graphic/57613.html" rel="external">picture 1</a>). </p><p></p><p>Serologic tests for antibody to <em>H. capsulatum</em> and culture of the organism are less rapid methods but can aid in confirming the diagnosis of disseminated histoplasmosis. (See <a class="local">'Antibody tests'</a> below and <a class="local">'Cultures'</a> below.)</p><p class="headingAnchor" id="H2221778599"><span class="h2">Diagnostic methods</span></p><p class="headingAnchor" id="H175079003"><span class="h3">Cultures</span><span class="headingEndMark"> — </span>Blood cultures should be performed in all suspected cases. Using the lysis-centrifugation technique, cultures are positive in about 65 percent of cases [<a href="#rid13">13-15</a>]. Bone marrow aspiration and biopsy for fungal stains and culture should be performed in patients who are anemic, leukopenic, and/or thrombocytopenic. In patients with diffuse pulmonary infiltrates, <em>H. capsulatum</em> can be cultured from respiratory and lung tissue in the majority of patients [<a href="#rid15">15</a>]. Depending on the sites involved, biopsy of the oral mucosa, skin, gastrointestinal tract, lymph nodes, adrenal glands, or liver can yield the organism in culture [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Cytology and histopathology</span><span class="headingEndMark"> — </span>Biopsy of a skin lesion, mucous membrane lesion, bone marrow, or other tissue can reveal the typical 2 to 4 micron yeast structures that demonstrate a single narrow-based bud of <em>H. capsulatum</em>. Although the organism can sometimes be demonstrated by hematoxylin and eosin stain, <em>H. capsulatum</em> is better visualized using methenamine silver or periodic acid-Schiff (PAS) stains. In one retrospective review, yeasts were seen using fungal stains in respiratory secretions in 86 percent, lung biopsy in 77 percent, and bone marrow in 60 percent of cases [<a href="#rid15">15</a>].</p><p>In the unusual circumstance of involvement of vascular structures, as occurs with endocarditis, histopathologic examination may reveal both yeast-like structures and hyphae  (<a class="graphic graphic_picture graphicRef96845" href="/z/d/graphic/96845.html" rel="external">picture 2</a>); the presence of hyphae was a prominent finding in a series of 14 cases of <em>Histoplasma</em> endocarditis [<a href="#rid16">16</a>]. Hyphae are not seen in typical cases of disseminated histoplasmosis that involve non-vascular organ systems.</p><p class="headingAnchor" id="H7"><span class="h3">Antibody tests</span><span class="headingEndMark"> — </span>Both the immunodiffusion test and the complement fixation test should be used in the evaluation of patients with suspected histoplasmosis. Although antibody assays are useful in the diagnosis of the chronic forms of disseminated histoplasmosis, they may be negative in acutely ill patients and are frequently negative in those who are immunocompromised. </p><p>In immunocompromised patients, detection of antibody depends upon the population tested. As an example, in one retrospective analysis, antibody was present in 83 percent of patients who had histoplasmosis and who were receiving TNF inhibitors [<a href="#rid17">17</a>]; however, in a series of patients who had undergone solid organ transplant, only 38 percent had antibody present [<a href="#rid18">18</a>]. The low sensitivity for antibody testing in some immunocompromised patients is attributed to the suppressive effects of underlying diseases and/or immunosuppressive medications [<a href="#rid19">19</a>].</p><p>An enzyme immunoassay antibody has been used as a screening test by some laboratories, but may be falsely negative in patients who have positive immunodiffusion or complement fixation tests. A newer enzyme immunoassay appears to be more sensitive than immunodiffusion and/or complement fixation in patients with acute pulmonary histoplasmosis [<a href="#rid20">20</a>], but the role of this test in the diagnosis of disseminated histoplasmosis is not clear. </p><p>Additional information on serologic testing is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2451.html" rel="external">"Diagnosis and treatment of pulmonary histoplasmosis", section on 'Serology'</a>.) </p><p class="headingAnchor" id="H205371829"><span class="h3">Antigen testing</span><span class="headingEndMark"> — </span>Tests for antigen in urine and serum should be performed in all patients suspected of having disseminated histoplasmosis. Antigen detection in serum may be positive in some cases when the results in urine are negative [<a href="#rid19">19,21,22</a>]. Antigen can also be detected in the cerebrospinal fluid (CSF) in most patients who have central nervous involvement and is a valuable diagnostic test when performed on bronchoalveolar lavage (BAL) fluid in patients who have pulmonary involvement.</p><p>Antigen testing is performed using an enzyme immunoassay (EIA). In results from the laboratory that developed this test (MiraVista Diagnostics), <em>Histoplasma</em> antigen was detected in the urine of approximately 75 percent of nonimmunocompromised and 95 percent of immunocompromised patients with disseminated disease [<a href="#rid19">19</a>]. <em>Histoplasma</em> antigen testing is now available from several different commercial laboratories, as well as through reference laboratories [<a href="#rid23">23-28</a>]. Comparison of these assays has shown variable results, but overall, it appears that the commercially available EIA tests are less sensitive than the original EIA [<a href="#rid10">10,26,28</a>]. Thus, a negative assay for antigen in serum or urine does not preclude the diagnosis of disseminated histoplasmosis, since the sensitivity of the various commercially available assays is variable.</p><p>False-positive EIA antigen results often occur in patients with blastomycosis and less frequently in patients with coccidioidomycosis, paracoccidioidomycosis, and talaromycosis (caused by <em>Talaromyces</em> <em>marneffei</em>, previously called <em>Penicillium marneffei</em>) [<a href="#rid22">22,29</a>]. False-positive results also have been noted in BAL fluid in patients with aspergillosis [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H1201676586"><span class="h3">Polymerase chain reaction</span><span class="headingEndMark"> — </span>The role of polymerase chain reaction (PCR) for diagnosis of histoplasmosis is not established and relies on assays developed and available at individual reference laboratories. One study that evaluated a small number of tissue and respiratory samples found 11 of 15 (73 percent) of culture-positive samples were positive by PCR [<a href="#rid31">31</a>], and in another, PCR was positive only if organisms were seen by microscopy [<a href="#rid32">32</a>]. A nested, real-time PCR assay was noted to have a sensitivity of 77 percent in a small number of clinical samples (serum, tissue, BAL) [<a href="#rid33">33</a>]. Using a real-time quantitative PCR assay that detects whole nucleic acids (both ribonucleic acid [RNA] and deoxyribonucleic acid [DNA]), the French Mycoses Study Group has reported sensitivity as high as 98 percent in patients with proven disseminated histoplasmosis. This assay was especially useful using specimens, including blood samples, taken from immunocompromised patients [<a href="#rid34">34</a>].  </p><p class="headingAnchor" id="H9"><span class="h2">Special considerations for diagnosing meningitis</span><span class="headingEndMark"> — </span>Establishing the diagnosis of meningitis due to histoplasmosis is difficult. For patients with suspected meningitis, CSF, serum, and urine testing should be obtained as summarized in the table  (<a class="graphic graphic_table graphicRef50806" href="/z/d/graphic/50806.html" rel="external">table 1</a>). (See <a class="local">'Antigen testing'</a> above and <a class="local">'Antibody tests'</a> above.)</p><p>Among patients with isolated meningitis, the diagnosis is often based upon detection of antigen or antibody in the CSF [<a href="#rid9">9,35-37</a>]. In a report that retrospectively evaluated CSF specimens in patients with a diagnosis of suspected or confirmed central nervous system (CNS) histoplasmosis, the diagnosis was improved when assays for both antigen and IgG/IgM antibody were performed [<a href="#rid37">37</a>]. In this specific study, a newly developed EIA assay for <em>Histoplasma </em>IgG/IgM appeared to perform better than the conventional complement fixation and immunodiffusion assays for detecting antibodies to <em>H. capsulatum </em>in the CSF. (See <a class="local">'Antibody tests'</a> above.)</p><p>Patients with meningitis may also have positive cultures from blood or other tissues. Fungal stains of CSF are rarely positive, and in one large series of 77 cases of <em>Histoplasma</em> CNS infection, only 38 percent of patients had <em>H. capsulatum</em> cultured from CSF [<a href="#rid36">36</a>]. To achieve the best diagnostic yield via culture of CSF, large volumes of CSF (10 to 20 mL) are required on at least two occasions. However, the diagnosis of histoplasmosis cannot be excluded even if large-volume lumbar spinal taps do not yield <em>H. capsulatum</em>. </p><p>In rare cases, when all of the above tests are negative, meningeal or brain biopsy may be needed to establish a diagnosis of meningeal or cerebral histoplasmosis [<a href="#rid35">35</a>].</p><p>There has been increasing interest in the use of 1,3-beta-D-glucan testing (Fungitell; Associates of Cape Cod, East Falmouth, Massachusetts, United States) in CSF for diagnosing fungal meningitis [<a href="#rid38">38</a>]. 1,3-beta-D-glucan is a cell wall component of many fungi, and during the nationwide outbreak of fungal CNS infections following injection of contaminated <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>, the beta-D-glucan assay was positive in some patients who had CNS infection with brown-black fungi [<a href="#rid39">39,40</a>]. Subsequent reports noted the utility of this assay in CSF in other fungal infections [<a href="#rid41">41,42</a>]. However, a positive 1,3-beta-D-glucan test alone is neither sensitive nor specific enough to establish the diagnosis of meningitis due to a specific causative organism. In one study of patients with <em>Histoplasma </em>meningitis, the sensitivity and specificity of the 1,3-beta-D-glucan test were 53 and 46 percent, respectively [<a href="#rid43">43</a>]. A positive test in the CSF is most useful in raising suspicion that an unexplained meningitis could be due to a fungus and prompting further testing, such as measuring CSF <em>Histoplasma</em> antigen and <em>Histoplasma</em> antibodies by complement fixation, immunodiffusion, and EIA methodologies [<a href="#rid37">37</a>]. (See <a class="local">'Antibody tests'</a> above.)</p><p class="headingAnchor" id="H1429082322"><span class="h2">Further diagnostic evaluation</span><span class="headingEndMark"> — </span>In patients without known underlying risk factors for disseminated histoplasmosis, careful immunologic investigation of cellular immunity, including T cell subset quantitation, should be considered, especially if disease relapses. Tests of lymphocyte proliferative response to <em>H. capsulatum</em> antigens and interferon-gamma release in response to <em>H. capsulatum</em> antigens are being developed and might possibly prove useful for diagnosis in the future [<a href="#rid44">44</a>]. Identification of new defects, such as those described in patients with abnormalities in cytokine pathways, will require specialized testing in laboratories that investigate cellular immune mechanisms [<a href="#rid45">45</a>]. </p><p class="headingAnchor" id="H78876651"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The most common symptoms of disseminated histoplasmosis are fever, fatigue, and weight loss. Symptoms and signs may point to involvement of specific sites, such as the oropharynx, gastrointestinal tract, central nervous system, and adrenal glands. (See  <a class="medical medical_review" href="/z/d/html/2455.html" rel="external">"Pathogenesis and clinical manifestations of disseminated histoplasmosis"</a>.)</p><p>The differential diagnosis includes malignancy, infection (eg, tuberculosis, other fungal diseases), or inflammatory disease (eg, inflammatory bowel disease, sarcoidosis). Misdiagnosis of an inflammatory process in a patient who actually has disseminated histoplasmosis may lead to inappropriate and harmful therapy with glucocorticoids, cytotoxic agents, or tumor necrosis factor-alpha inhibitors [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/2451.html" rel="external">"Diagnosis and treatment of pulmonary histoplasmosis", section on 'Distinction from sarcoidosis'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The approach to treatment depends upon the severity of disease as well as the presence of central nervous system (CNS) involvement. Our approach to the management of patients with histoplasmosis is consistent with clinical practice guidelines by the Infectious Diseases Society of America [<a href="#rid47">47</a>]. </p><p class="headingAnchor" id="H421842445"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Treatment is indicated for all patients with disseminated histoplasmosis [<a href="#rid47">47</a>]. The natural history of untreated acute disseminated infection is progressive and fatal over a 2- to 12-week course. The less common chronic form of disseminated histoplasmosis is often present for months before diagnosis [<a href="#rid4">4</a>]. In this chronic form, recurrent illness, separated by asymptomatic periods ranging from several years up to two decades, rarely may be seen, but the disease ultimately will prove fatal if not treated [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H2397156121"><span class="h2">Patients without CNS disease</span></p><p class="headingAnchor" id="H1219092862"><span class="h3">Approach to treatment</span><span class="headingEndMark"> — </span>For patients without central nervous system (CNS) involvement, the treatment of disseminated histoplasmosis typically involves the use of amphotericin B (preferably one of its lipid formulations) or an azole drug, such as <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> [<a href="#rid48">48</a>]. Dosing recommendations are discussed below. (See <a class="local">'Antifungal agents'</a> below.)</p><p>Agent selection depends primarily upon disease severity  (<a class="graphic graphic_table graphicRef57457" href="/z/d/graphic/57457.html" rel="external">table 2</a>). Summarized briefly:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with severe disease </strong>– One of the lipid formulations of amphotericin B should be used in patients who are sufficiently ill to require hospitalization. <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">Itraconazole</a> is not used for initial therapy in such patients because it does not eradicate fungemia as rapidly as amphotericin B, and serum levels do not reach a steady state for several weeks [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">Most patients respond quickly to amphotericin B and then can be transitioned to <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> after one to two weeks. The transition from amphotericin B to itraconazole should occur after the patient becomes afebrile; no longer requires blood pressure or ventilatory support, or intravenous fluids; and is able to take oral medications. It is helpful to start therapy with itraconazole during the last few days of amphotericin B therapy to make it more likely that serum concentrations of itraconazole will be measurable before amphotericin B therapy is discontinued.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with mild to moderate symptoms</strong> – <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">Itraconazole</a> is the treatment of choice for patients who have mild to moderate symptoms [<a href="#rid50">50,51</a>]. </p><p></p><p>In pregnant women, the approach to treatment must be determined on a case-by-case basis. Azoles are contraindicated in the first trimester because of the risk of teratogenicity, and use later in pregnancy must balance possible risks with benefits. </p><p>The total duration of treatment should be at least one year. Although the optimal duration of <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> therapy has not been specifically studied, therapy for at least one year is preferred because it may reduce the risk for relapse. However, there are no clinical trials that have studied this. Duration may sometimes need to be extended in patients at high risk for relapse of histoplasmosis because their immunosuppression cannot be reversed (eg, transplant recipients). This is discussed below. (See <a class="local">'Concurrent immunosuppressive therapy'</a> below.)</p><p>If <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> is not tolerated, oral therapy with <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a>, or <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> are other options. However, there are limited data to guide agent selection in this setting. Fluconazole appears to be less effective than itraconazole, and there are data that suggest that voriconazole is not as efficacious as itraconazole [<a href="#rid52">52,53</a>]. The extended-release formulation of posaconazole has advantages over voriconazole because it results in more consistent serum levels and has fewer side effects. There is limited experience with isavuconazole for treatment of histoplasmosis [<a href="#rid54">54</a>]. There are no clinical trials that have directly compared different azoles for treatment of histoplasmosis. When any azole is used, it is important to assess for drug-drug interactions (especially in transplant recipients) and to measure serum concentrations to ensure therapeutic levels and avoid toxicity [<a href="#rid55">55</a>]. (See <a class="local">'Antifungal agents'</a> below.)</p><p>For patients who develop adrenal insufficiency associated with disseminated histoplasmosis, the changes are usually irreversible, and lifelong maintenance <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> therapy will be required. Patients must be warned about the dangers inherent in stopping replacement therapy. (See  <a class="medical medical_review" href="/z/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a>.)</p><p class="headingAnchor" id="H922146573"><span class="h3">Antifungal agents</span><span class="headingEndMark"> — </span>Information regarding the use of specific antifungal agents for the treatment of disseminated histoplasmosis will be reviewed in this section. Regimen selection is discussed above. (See <a class="local">'Approach to treatment'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amphotericin B</strong> – The lipid formulations of amphotericin B (eg, AmBisome or Abelcet) require doses of 3 to 5 mg/kg per day  (<a class="graphic graphic_table graphicRef57457" href="/z/d/graphic/57457.html" rel="external">table 2</a>) [<a href="#rid56">56</a>]. If the deoxycholate formulation is used, a dose of 0.7 to 1.0 mg/kg per day is recommended. (See  <a class="medical medical_review" href="/z/d/html/476.html" rel="external">"Pharmacology of amphotericin B"</a>.)</p><p></p><p class="bulletIndent1">A randomized, controlled trial showed that induction therapy with <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> at a dose of 3 mg/kg/day produced better outcomes than the deoxycholate formulation [<a href="#rid56">56</a>]. Among 81 patients with AIDS and moderately severe to severe disseminated histoplasmosis, liposomal amphotericin B was associated with the following significant benefits: a higher rate of clinical success (88 versus 64 percent) despite similar rates of culture conversion, and lower rates of mortality (2 versus 13 percent), infusion-related side effects (25 versus 63 percent), and nephrotoxicity (9 versus 37 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Itraconazole</strong> – <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">Itraconazole</a> capsules should be administered with food at a loading dose of 200 mg three times daily for three days to achieve steady-state serum concentrations more rapidly, and then 200 mg twice daily. Acid-blocking drugs should be avoided when the capsule formulation is given. A cola beverage, in addition to a meal, can be administered with the tablets, presumably to increase gastric acidity. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles"</a>.)</p><p></p><p class="bulletIndent1">The liquid formulation of <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> overcomes problems caused by poor absorption of the capsule formulation and achieves approximately 30 percent higher concentrations in the serum at the same dose. The solution should be given on an empty stomach to achieve the highest serum concentrations. However, more gastrointestinal upset occurs with the solution formulation, which precludes its use in some patients. </p><p></p><p class="bulletIndent1">A newer formulation of <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> with enhanced bioavailability, SUBA-itraconazole, was approved for use in the United States in 2018 [<a href="#rid57">57</a>]. Studies on its use for prophylaxis against invasive fungal infections in recipients of lung transplants and hematopoietic cell transplants have shown efficacy and safety in these populations [<a href="#rid58">58,59</a>]. The role of SUBA-itraconazole in the treatment of histoplasmosis has been evaluated in a Mycoses Study Group trial and results have yet to be published. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">Itraconazole</a> levels should be measured after two weeks of therapy when the drug has reached steady state [<a href="#rid47">47</a>]. The dose should be adjusted to achieve a serum concentration of 1 to 2 mcg/mL, determined by adding together the itraconazole parent drug concentration and the hydroxy-itraconazole concentration measured by high-performance liquid chromatography (HPLC). If a bioassay is used, rather than HPLC, the levels are at least three times higher, and a concentration of 3 to 6 mcg/mL is recommended. The timing of the specimen following the dose is not critical because of itraconazole's long half-life. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Itraconazole'</a>.)</p><p></p><p class="bulletIndent1">The factors that affect <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> pharmacokinetics, including drug interactions, absorption, and drug formulation, are discussed in detail separately (see  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Drug interactions'</a>). Indications to repeat serum measurements include initially low values, dose modification, concern about compliance or absorption, initiation of treatment with potentially interacting medications, and suspicion of relapse.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluconazole</strong> – <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> should be reserved for treatment of histoplasmosis in patients who cannot take <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>. The fluconazole dose should be at least 400 mg/day in immunocompetent individuals and 800 mg/day in patients with HIV or other immunocompromising conditions. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> is not as active in vitro against <em>H. capsulatum</em> as <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> and has not been as effective when used for treatment [<a href="#rid53">53,60</a>], in part because fungemia is cleared more slowly [<a href="#rid61">61</a>]. In one study, 75 percent of patients with AIDS who had mild or moderately severe disease responded to fluconazole (800 mg/day); however, nearly one-third relapsed while receiving 400 mg/day as chronic maintenance therapy [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1">Another problem with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> is the development of resistance [<a href="#rid62">62</a>]. In one report, one-half of <em>Histoplasma</em> strains from patients with AIDS who failed fluconazole therapy had developed in vitro resistance to the drug [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Voriconazole</strong> – <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">Voriconazole</a>, similar to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, is less active than <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> and <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> in vitro and, in some studies, was less effective [<a href="#rid52">52,63</a>]. It has been used successfully in a small number of patients with disseminated histoplasmosis, including those who had CNS infection and who failed or could not tolerate other therapy [<a href="#rid48">48,52,55,64-68</a>], but no clinical treatment trials have been conducted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posaconazole</strong> – Similar to <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>, <em>H. capsulatum</em> is highly susceptible to <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> [<a href="#rid63">63</a>]. No clinical treatment trials have been reported but this agent has been shown to be effective in individual case reports [<a href="#rid48">48,69-72</a>]. The extended-release tablet formulation achieves predictable serum concentrations and is often better tolerated than itraconazole.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isavuconazole</strong> – <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">Isavuconazole</a> is active in vitro against <em>H. capsulatum</em> [<a href="#rid73">73</a>]. A few patients with histoplasmosis, including one with CNS infection, have been reported to have successful outcomes with isavuconazole [<a href="#rid54">54,73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Echinocandins</strong> – <em>H. capsulatum</em> is <strong>not </strong>susceptible to the echinocandins and they should not be used to treat this infection [<a href="#rid74">74</a>]. </p><p></p><p class="headingAnchor" id="H16"><span class="h3">Drug interactions</span><span class="headingEndMark"> — </span>All azoles are associated with a variety of drug interactions that may influence the choice of medication or dosing. These include drugs that can accelerate or impair the metabolism of an azole agent and drugs whose metabolism is slowed by the azoles. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Drug interactions'</a> and  <a class="drug drug_patient" href="/z/d/drug information/10780.html" rel="external">"Itraconazole: Patient drug information"</a> and  <a class="drug drug_patient" href="/z/d/drug information/12475.html" rel="external">"Fluconazole: Patient drug information"</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Monitoring response to therapy</span><span class="headingEndMark"> — </span><em>Histoplasma</em> antigen concentrations in the urine and serum fall with effective therapy and should be checked every few months during therapy and up to six months after completion of therapy to determine early signs of relapse [<a href="#rid75">75</a>]. Rising antigen values raise concern for relapse. </p><p>Reasons for treatment failure or relapse include: low <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> blood concentrations; poor adherence to medications; and resistance to antifungal agents, although the latter is uncommon. Patients who experience treatment failure or relapse should be managed in consultation with an infectious diseases provider experienced in the treatment of histoplasmosis. </p><p class="headingAnchor" id="H11961449"><span class="h2">Patients with CNS disease</span><span class="headingEndMark"> — </span>For patients with central nervous system (CNS) histoplasmosis, aggressive therapy is recommended to achieve the greatest chance for a successful outcome. Treatment for <em>Histoplasma</em> meningitis is difficult because of the poor penetration of most antifungal agents into the CSF. In one older report, only 60 to 80 percent of patients with meningitis responded to treatment with amphotericin B, and up to one-half of responders relapsed during subsequent years [<a href="#rid9">9</a>]. </p><p>Our general approach to treatment is described below. However, a clinician with experience in managing patients with CNS histoplasmosis should be consulted. Management may be particularly challenging in pregnant women, as azoles are contraindicated in the first trimester because of the risk of teratogenicity, and use later in pregnancy must balance possible risks with benefits. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobial therapy</strong> – We administer <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (AmBisome, 5 mg/kg intravenously daily) for four to six weeks. A similar dose and duration of therapy is recommended if the lipid complex formulation (Abelcet) is used. Dose reduction or earlier transition to <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> may be needed in patients who develop renal impairment while taking amphotericin B. </p><p></p><p class="bulletIndent1">Following induction therapy, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> (200 mg orally twice or three times daily) should be given for at least one year to help prevent relapse. However, some clinicians will treat with an azole for life rather than stopping after one year, given the risk of relapse. Measurement of blood concentrations of itraconazole early in the course of therapy and at intervals throughout therapy is recommended to ensure adequate serum levels [<a href="#rid35">35</a>]. (See <a class="local">'Antifungal agents'</a> above.)</p><p></p><p class="bulletIndent1">In patients unable to tolerate <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>, high-dose <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (800 mg daily) is an alternative, as is <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, which achieves excellent concentrations in the cerebrospinal fluid (CSF) [<a href="#rid64">64,65,68</a>]. The dose of voriconazole will depend on the serum concentrations achieved as well as the development of adverse effects. A reasonable starting dose would be 400 mg twice daily for one day followed by 200 mg twice daily. If concentrations of 2 to 5 mcg/mL are not achieved by day 5, the dose should be increased. Doses as high as 400 mg twice daily may be required. </p><p></p><p class="bulletIndent1">This rationale for this approach is based on findings that <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (AmBisome) achieves higher concentrations in the brain than other lipid formulations or <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, providing a theoretical basis for its use in CNS histoplasmosis. Although <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> achieves excellent concentrations in the CSF [<a href="#rid76">76</a>], this agent was less effective than amphotericin B as monotherapy, and fluconazole plus amphotericin B was less effective than amphotericin B alone in an experimental model of <em>Histoplasma</em> meningitis [<a href="#rid77">77</a>]. <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">Itraconazole</a>, although more active than fluconazole against <em>H. capsulatum</em>, does not achieve measurable concentrations in the CSF [<a href="#rid78">78</a>]. However, this agent has been used successfully in the treatment of <em>Histoplasma</em> meningitis, as well as other fungal meningitides. Individual case reports have noted success with the other azoles in individual patients [<a href="#rid64">64,65,68,69,73</a>]. (See <a class="local">'Antifungal agents'</a> above.)</p><p></p><p class="bulletIndent1">Administration of amphotericin B directly into the ventricles, cisterna magna, or lumbar arachnoid space is rarely, if ever, indicated; evidence is lacking for its effectiveness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Patients with CNS histoplasmosis who respond to initial therapy should be followed closely for symptoms and signs of relapse of infection. Lumbar puncture should be repeated every few months to evaluate the patient's response to treatment; CSF studies include protein, glucose, white blood cell count, culture (if it was positive initially), and antigen tests. Laboratory testing should also include <em>Histoplasma</em> antigen from the serum and urine. </p><p></p><p class="bulletIndent1">There are no data to guide the frequency of monitoring. If <em>Histoplasma</em> antigen tests were positive in urine or serum, we repeat these tests monthly for the first few months and then approximately every three months thereafter. A rise in serum or urine antigen level or reversion from negative to positive is worrisome for relapse, which is best evaluated by measuring the CSF antigen level. Additional information on monitoring is discussed above. (See <a class="local">'Monitoring response to therapy'</a> above.)</p><p></p><p class="bulletIndent1">Relapse despite chronic suppressive therapy is an indication for repeat treatment with intravenous <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a>. </p><p></p><p class="headingAnchor" id="H4288909414"><span class="h2">Concurrent immunosuppressive therapy</span><span class="headingEndMark"> — </span>For patients taking immunosuppressive therapy at the time of histoplasmosis diagnosis, questions arise regarding how to manage the immunosuppressive agents. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minimizing immunosuppression initially</strong> – For patients who develop disseminated histoplasmosis while taking immunosuppressive biologic agents, such as TNF-alpha inhibitors, the standard of practice is to stop the agent for at least several months to allow the patient to respond to the antifungal drug and control the infection [<a href="#rid17">17</a>]. For transplant recipients for whom immunosuppression cannot be stopped totally, minimizing the amount of immunosuppression as much as possible for at least several months should be the goal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Restarting immunosuppressive therapy</strong> – The decision whether and when to start back on immunosuppressive therapy should be made together with the physician caring for the underlying disease that requires immunosuppression, the infectious diseases consultant, and the patient. Occasionally, an autoimmune disease may be under control and further immunosuppression may not be necessary. In other cases, another immunosuppressive agent with less conferred risk for disseminated histoplasmosis can be used instead. When the patient’s disease does require further immunosuppressive therapy with the same drug as before, we monitor closely with frequent visits and labs (eg, urine histoplasma antigen) to confirm continued response to antifungal drugs. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of histoplasmosis therapy</strong> – For those who are at high risk for relapse of histoplasmosis because their immunosuppression cannot be reversed (eg, transplant recipients, ongoing use of a TNF-alpha inhibitor), long-term or lifelong maintenance therapy is reasonable [<a href="#rid17">17,18,21,79</a>]. Important points to consider in this decision are the extent of the histoplasmosis (eg, whether CNS infection is present, making relapse more likely); the response to antifungals (eg, has the antigen concentration fallen to undetectable and is the patient symptom-free); and the probability that the patient can be followed closely for signs of relapse after the antifungals are stopped over the ensuing months to years. For patients who remain on long-term or lifelong maintenance therapy, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> is given at a dose of 200 mg once or twice daily. </p><p></p><p>Evidence to guide decision-making in these circumstances is scarce. There are no controlled trials to answer the above questions, and decisions must be made on a case-by-case basis. </p><p>Maintenance therapy in patients with HIV is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6996.html" rel="external">"Treatment of histoplasmosis in patients with HIV", section on 'Maintenance therapy'</a>.)</p><p class="headingAnchor" id="H875123532"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>In the period before amphotericin B was introduced, disseminated histoplasmosis, whether acute or chronic, was fatal for all but a few patients [<a href="#rid4">4,80</a>]. <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">Amphotericin B deoxycholate</a> therapy changed the prognosis greatly, but relapses were common, primarily because long-term therapy with amphotericin B deoxycholate was extremely difficult [<a href="#rid6">6</a>]. Follow-up therapy of severe disseminated histoplasmosis and primary therapy of mild to moderate histoplasmosis with azole antifungal agents noted a continued decrease in mortality and prevented the occurrence of relapses [<a href="#rid15">15,51,56,81,82</a>]. Survival rates for patients with disseminated histoplasmosis now approach 90 percent. Patients with severe immune compromise have a worse prognosis, in general, but even in this population, the available treatment options ensure good outcomes in most patients [<a href="#rid15">15,55,56,81</a>].</p><p class="headingAnchor" id="H3656473775"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120865.html" rel="external">"Society guideline links: Histoplasmosis"</a>.)</p><p class="headingAnchor" id="H475417282"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/87577.html" rel="external">"Patient education: Histoplasmosis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of disease </strong>–<strong> </strong>Histoplasmosis is the most prevalent endemic mycosis in the United States. Most infections are asymptomatic or self-limited, but some individuals develop acute pulmonary infection or severe disseminated disease. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>When to suspect disseminated histoplasmosis </strong>–<strong> </strong>The diagnosis of disseminated histoplasmosis should be suspected in patients with risk factors for disease (eg, immunosuppression or extremes of age and risk factors for exposure) in combination with clinical manifestations that are consistent with disseminated histoplasmosis. (See <a class="local">'When to suspect the diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Establishing the diagnosis </strong>–<strong> </strong>Microscopic demonstration or isolation of <em>Histoplasma</em> from extrapulmonary sites provides proof of dissemination in patients with histoplasmosis. Histopathology using stains for fungi, cultures, antigen detection, and tests for <em>Histoplasma</em>-specific antibodies can all be used to help make the diagnosis. (See <a class="local">'Establishing the diagnosis'</a> above and <a class="local">'Diagnostic methods'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis CNS histoplasmosis </strong>–<strong> </strong>Establishing the diagnosis of meningitis due to histoplasmosis can be difficult; thus, for patients with suspected meningitis, cerebrospinal fluid (CSF), serum, and urine antigen testing, CSF and serum antibody testing, and CSF and blood cultures should be obtained  (<a class="graphic graphic_table graphicRef50806" href="/z/d/graphic/50806.html" rel="external">table 1</a>). The diagnosis is often based upon detection of antigen or antibody in the CSF as CSF cultures are often not positive. (See <a class="local">'Special considerations for diagnosing meningitis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>–<strong> </strong>Treatment is indicated for all patients with disseminated histoplasmosis. The natural history is progressive and fatal over a 2- to 12-week course in those with untreated acute disseminated infection, versus months to years in those with untreated chronic disseminated histoplasmosis. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Histoplasmosis without CNS involvement </strong>–<strong> </strong>For patients without central nervous system (CNS) involvement, the choice of agent depends primarily upon disease severity  (<a class="graphic graphic_table graphicRef57457" href="/z/d/graphic/57457.html" rel="external">table 2</a>). (See <a class="local">'Patients without CNS disease'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Severe disease </strong>–<strong> </strong>For patients with severe disease (eg, those requiring hospitalization), one of the lipid formulations of amphotericin B should be initiated (eg, AmBisome at 3 mg/kg per day or Abelcet at 5 mg/kg per day). <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">Itraconazole</a> is not recommended for initial therapy in such patients since it does not eradicate fungemia as rapidly as amphotericin. However, most patients can be transitioned to oral itraconazole within one to two weeks. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Mild to moderate disease </strong>–<strong> </strong>For those with mild to moderate disease, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> is the treatment of choice.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CNS histoplasmosis </strong>–<strong> </strong>For patients with CNS histoplasmosis, we administer <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (AmBisome, 5 mg/kg intravenously daily) for four to six weeks. A similar dose and duration of therapy is recommended if the lipid complex formulation (Abelcet) is used. Following induction therapy, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> (200 mg orally twice or three times daily) should be given for at least one year to prevent relapse. (See <a class="local">'Patients with CNS disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration</strong> – The total duration of treatment should be at least one year. Long-term or sometimes lifelong suppressive therapy is reasonable for those who are at risk for relapse of histoplasmosis because their immunosuppression cannot be reversed (eg, transplant recipients). (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring response to therapy</strong> – <em>Histoplasma</em> antigen concentrations in the urine and serum fall with effective therapy and should be monitored at regular intervals. Patients with CNS histoplasmosis also require monitoring of CSF. (See <a class="local">'Monitoring response to therapy'</a> above and <a class="local">'Patients with CNS disease'</a> above.)</p><p></p><p class="headingAnchor" id="H2871794744"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Joseph Wheat, MD, and Kieren Marr, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chu JH, Feudtner C, Heydon K, et al. Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis 2006; 42:822.</a></li><li><a class="nounderline abstract_t">Colombo AL, Tobón A, Restrepo A, et al. Epidemiology of endemic systemic fungal infections in Latin America. Med Mycol 2011; 49:785.</a></li><li><a class="nounderline abstract_t">Nieto-Ríos JF, Serna-Higuita LM, Guzman-Luna CE, et al. Histoplasmosis in renal transplant patients in an endemic area at a reference hospital in Medellin, Colombia. Transplant Proc 2014; 46:3004.</a></li><li><a class="nounderline abstract_t">Goodwin RA Jr, Shapiro JL, Thurman GH, et al. Disseminated histoplasmosis: clinical and pathologic correlations. Medicine (Baltimore) 1980; 59:1.</a></li><li><a class="nounderline abstract_t">Wheat LJ. Improvements in diagnosis of histoplasmosis. Expert Opin Biol Ther 2006; 6:1207.</a></li><li><a class="nounderline abstract_t">Sathapatayavongs B, Batteiger BE, Wheat J, et al. Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. Medicine (Baltimore) 1983; 62:263.</a></li><li><a class="nounderline abstract_t">Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990; 69:361.</a></li><li><a class="nounderline abstract_t">Conces DJ Jr, Stockberger SM, Tarver RD, Wheat LJ. Disseminated histoplasmosis in AIDS: findings on chest radiographs. AJR Am J Roentgenol 1993; 160:15.</a></li><li><a class="nounderline abstract_t">Wheat LJ, Batteiger BE, Sathapatayavongs B. Histoplasma capsulatum infections of the central nervous system. A clinical review. Medicine (Baltimore) 1990; 69:244.</a></li><li><a class="nounderline abstract_t">Azar MM, Hage CA. Laboratory Diagnostics for Histoplasmosis. J Clin Microbiol 2017; 55:1612.</a></li><li><a class="nounderline abstract_t">Falci DR, Hoffmann ER, Paskulin DD, Pasqualotto AC. Progressive disseminated histoplasmosis: a systematic review on the performance of non-culture-based diagnostic tests. Braz J Infect Dis 2017; 21:7.</a></li><li><a class="nounderline abstract_t">Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev 2007; 20:115.</a></li><li><a class="nounderline abstract_t">Fuller DD, Davis TE Jr, Denys GA, York MK. Evaluation of BACTEC MYCO/F Lytic medium for recovery of mycobacteria, fungi, and bacteria from blood. J Clin Microbiol 2001; 39:2933.</a></li><li><a class="nounderline abstract_t">Lyon R, Woods G. Comparison of the BacT/Alert and Isolator blood culture systems for recovery of fungi. Am J Clin Pathol 1995; 103:660.</a></li><li><a class="nounderline abstract_t">Assi MA, Sandid MS, Baddour LM, et al. Systemic histoplasmosis: a 15-year retrospective institutional review of 111 patients. Medicine (Baltimore) 2007; 86:162.</a></li><li><a class="nounderline abstract_t">Riddell J 4th, Kauffman CA, Smith JA, et al. Histoplasma capsulatum endocarditis: multicenter case series with review of current diagnostic techniques and treatment. Medicine (Baltimore) 2014; 93:186.</a></li><li><a class="nounderline abstract_t">Vergidis P, Avery RK, Wheat LJ, et al. Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases. Clin Infect Dis 2015; 61:409.</a></li><li><a class="nounderline abstract_t">Assi M, Martin S, Wheat LJ, et al. Histoplasmosis after solid organ transplant. Clin Infect Dis 2013; 57:1542.</a></li><li><a class="nounderline abstract_t">Hage CA, Ribes JA, Wengenack NL, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis 2011; 53:448.</a></li><li><a class="nounderline abstract_t">Richer SM, Smedema ML, Durkin MM, et al. Improved Diagnosis of Acute Pulmonary Histoplasmosis by Combining Antigen and Antibody Detection. Clin Infect Dis 2016; 62:896.</a></li><li><a class="nounderline abstract_t">Hage CA, Bowyer S, Tarvin SE, et al. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis 2010; 50:85.</a></li><li><a class="nounderline abstract_t">Connolly PA, Durkin MM, Lemonte AM, et al. Detection of histoplasma antigen by a quantitative enzyme immunoassay. Clin Vaccine Immunol 2007; 14:1587.</a></li><li><a class="nounderline abstract_t">Scheel CM, Samayoa B, Herrera A, et al. Development and evaluation of an enzyme-linked immunosorbent assay to detect Histoplasma capsulatum antigenuria in immunocompromised patients. Clin Vaccine Immunol 2009; 16:852.</a></li><li><a class="nounderline abstract_t">Lindsley MD, Holland HL, Bragg SL, et al. Production and evaluation of reagents for detection of Histoplasma capsulatum antigenuria by enzyme immunoassay. Clin Vaccine Immunol 2007; 14:700.</a></li><li><a class="nounderline abstract_t">Cloud JL, Bauman SK, Neary BP, et al. Performance characteristics of a polyclonal enzyme immunoassay for the quantitation of Histoplasma antigen in human urine samples. Am J Clin Pathol 2007; 128:18.</a></li><li><a class="nounderline abstract_t">Theel ES, Jespersen DJ, Harring J, et al. Evaluation of an enzyme immunoassay for detection of Histoplasma capsulatum antigen from urine specimens. J Clin Microbiol 2013; 51:3555.</a></li><li><a class="nounderline abstract_t">Theel ES, Harring JA, Dababneh AS, et al. Reevaluation of commercial reagents for detection of Histoplasma capsulatum antigen in urine. J Clin Microbiol 2015; 53:1198.</a></li><li><a class="nounderline abstract_t">Zhang C, Lei GS, Lee CH, Hage CA. Evaluation of two new enzyme immunoassay reagents for diagnosis of histoplasmosis in a cohort of clinically characterized patients. Med Mycol 2015; 53:868.</a></li><li><a class="nounderline abstract_t">Wheat J, Wheat H, Connolly P, et al. Cross-reactivity in Histoplasma capsulatum variety capsulatum antigen assays of urine samples from patients with endemic mycoses. Clin Infect Dis 1997; 24:1169.</a></li><li><a class="nounderline abstract_t">Hage CA, Davis TE, Fuller D, et al. Diagnosis of histoplasmosis by antigen detection in BAL fluid. Chest 2010; 137:623.</a></li><li><a class="nounderline abstract_t">Babady NE, Buckwalter SP, Hall L, et al. Detection of Blastomyces dermatitidis and Histoplasma capsulatum from culture isolates and clinical specimens by use of real-time PCR. J Clin Microbiol 2011; 49:3204.</a></li><li><a class="nounderline abstract_t">Bialek R, Cirera AC, Herrmann T, et al. Nested PCR assays for detection of Blastomyces dermatitidis DNA in paraffin-embedded canine tissue. J Clin Microbiol 2003; 41:205.</a></li><li><a class="nounderline abstract_t">Muraosa Y, Toyotome T, Yahiro M, et al. Detection of Histoplasma capsulatum from clinical specimens by cycling probe-based real-time PCR and nested real-time PCR. Med Mycol 2016; 54:433.</a></li><li><a class="nounderline abstract_t">Alanio A, Gits-Muselli M, Lanternier F, et al. Evaluation of a New Histoplasma spp. Quantitative RT-PCR Assay. J Mol Diagn 2021; 23:698.</a></li><li><a class="nounderline abstract_t">Wheat LJ, Musial CE, Jenny-Avital E. Diagnosis and management of central nervous system histoplasmosis. Clin Infect Dis 2005; 40:844.</a></li><li><a class="nounderline abstract_t">Wheat J, Myint T, Guo Y, et al. Central nervous system histoplasmosis: Multicenter retrospective study on clinical features, diagnostic approach and outcome of treatment. Medicine (Baltimore) 2018; 97:e0245.</a></li><li><a class="nounderline abstract_t">Bloch KC, Myint T, Raymond-Guillen L, et al. Improvement in Diagnosis of Histoplasma Meningitis by Combined Testing for Histoplasma Antigen and Immunoglobulin G and Immunoglobulin M Anti-Histoplasma Antibody in Cerebrospinal Fluid. Clin Infect Dis 2018; 66:89.</a></li><li><a class="nounderline abstract_t">Tran T, Beal SG. Application of the 1,3-β-D-Glucan (Fungitell) Assay in the Diagnosis of Invasive Fungal Infections. Arch Pathol Lab Med 2016; 140:181.</a></li><li><a class="nounderline abstract_t">Malani AN, Singal B, Wheat LJ, et al. (1,3)-β-d-glucan in cerebrospinal fluid for diagnosis of fungal meningitis associated with contaminated methylprednisolone injections. J Clin Microbiol 2015; 53:799.</a></li><li><a class="nounderline abstract_t">Litvintseva AP, Lindsley MD, Gade L, et al. Utility of (1-3)-β-D-glucan testing for diagnostics and monitoring response to treatment during the multistate outbreak of fungal meningitis and other infections. Clin Infect Dis 2014; 58:622.</a></li><li><a class="nounderline abstract_t">Lyons JL, Thakur KT, Lee R, et al. Utility of measuring (1,3)-β-d-glucan in cerebrospinal fluid for diagnosis of fungal central nervous system infection. J Clin Microbiol 2015; 53:319.</a></li><li><a class="nounderline abstract_t">Stevens DA, Zhang Y, Finkelman MA, et al. Cerebrospinal Fluid (1,3)-Beta-d-Glucan Testing Is Useful in Diagnosis of Coccidioidal Meningitis. J Clin Microbiol 2016; 54:2707.</a></li><li><a class="nounderline abstract_t">Myint T, Chow FC, Bloch KC, et al. Detection of (1,3)-β-d-Glucan in Cerebrospinal Fluid in Histoplasma Meningitis. J Clin Microbiol 2018; 56.</a></li><li><a class="nounderline abstract_t">Rubio-Carrasquilla M, Santa CD, Rendón JP, et al. An interferon gamma release assay specific for Histoplasma capsulatum to detect asymptomatic infected individuals: A proof of concept study. Med Mycol 2019; 57:724.</a></li><li><a class="nounderline abstract_t">Lionakis MS, Netea MG, Holland SM. Mendelian genetics of human susceptibility to fungal infection. Cold Spring Harb Perspect Med 2014; 4.</a></li><li><a class="nounderline abstract_t">Gulati M, Saint S, Tierney LM Jr. Clinical problem-solving. Impatient inpatient care. N Engl J Med 2000; 342:37.</a></li><li><a class="nounderline abstract_t">Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807.</a></li><li><a class="nounderline abstract_t">Kauffman CA. Treatment of the midwestern endemic mycoses, histoplasmosis and blastomycosis. Curr Fungal Infect Rep 2017; 11:67.</a></li><li><a class="nounderline abstract_t">Wheat LJ, Cloud G, Johnson PC, et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob Agents Chemother 2001; 45:2354.</a></li><li><a class="nounderline abstract_t">Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med 1995; 98:336.</a></li><li><a class="nounderline abstract_t">Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med 1992; 93:489.</a></li><li><a class="nounderline abstract_t">Hendrix MJ, Larson L, Rauseo AM, et al. Voriconazole Versus Itraconazole for the Initial and Step-down Treatment of Histoplasmosis: A Retrospective Cohort. Clin Infect Dis 2021; 73:e3727.</a></li><li><a class="nounderline abstract_t">McKinsey DS, Kauffman CA, Pappas PG, et al. Fluconazole therapy for histoplasmosis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1996; 23:996.</a></li><li><a class="nounderline abstract_t">Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, et al. Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. Clin Infect Dis 2016; 63:356.</a></li><li><a class="nounderline abstract_t">Kauffman CA, Freifeld AG, Andes DR, et al. Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET). Transpl Infect Dis 2014; 16:213.</a></li><li><a class="nounderline abstract_t">Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137:105.</a></li><li class="breakAll">Tolsura (itraconazole capsules), for oral use, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208901s000lbl.pdf (Accessed on December 04, 2023).</li><li><a class="nounderline abstract_t">Whitmore TJ, Yaw M, Lavender M, et al. A novel highly bio-available itraconazole formulation (SUBA®-Itraconazole) for anti-fungal prophylaxis in lung transplant recipients. Transpl Infect Dis 2021; 23:e13587.</a></li><li><a class="nounderline abstract_t">Nield B, Larsen SR, van Hal SJ. Clinical experience with new formulation SUBA®-itraconazole for prophylaxis in patients undergoing stem cell transplantation or treatment for haematological malignancies. J Antimicrob Chemother 2019; 74:3049.</a></li><li><a class="nounderline abstract_t">Wheat J, MaWhinney S, Hafner R, et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Am J Med 1997; 103:223.</a></li><li><a class="nounderline abstract_t">Wheat LJ, Connolly P, Haddad N, et al. Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrob Agents Chemother 2002; 46:248.</a></li><li><a class="nounderline abstract_t">Wheat LJ, Connolly P, Smedema M, et al. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin Infect Dis 2001; 33:1910.</a></li><li><a class="nounderline abstract_t">Wheat LJ, Connolly P, Smedema M, et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother 2006; 57:1235.</a></li><li><a class="nounderline abstract_t">Prinapori R, Mikulksa M, Parisini A, et al. A case of cerebral histoplasmosis in an immunocompetent host successfully treated with voriconazole. Infect Dis Trop Med 2015; 1:e90.</a></li><li><a class="nounderline abstract_t">Ramireddy S, Wanger A, Ostrosky L. An instructive case of CNS histoplasmosis in an immunocompetent host. Med Mycol Case Rep 2012; 1:69.</a></li><li><a class="nounderline abstract_t">Freifeld A, Proia L, Andes D, et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 2009; 53:1648.</a></li><li><a class="nounderline abstract_t">Dhawan J, Verma P, Sharma A, et al. Disseminated cutaneous histoplasmosis in an immunocompetent child, relapsed with itraconazole, successfully treated with voriconazole. Pediatr Dermatol 2010; 27:549.</a></li><li><a class="nounderline abstract_t">Srinivasan J, Ooi WW. Successful treatment of histoplasmosis brain abscess with voriconazole. Arch Neurol 2008; 65:666.</a></li><li><a class="nounderline abstract_t">Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56:745.</a></li><li><a class="nounderline abstract_t">Restrepo A, Tobón A, Clark B, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect 2007; 54:319.</a></li><li><a class="nounderline abstract_t">Clark B, Foster R, Tunbridge A, Green S. A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole. J Infect 2005; 51:e177.</a></li><li><a class="nounderline abstract_t">Schulze AB, Heptner B, Kessler T, et al. Progressive histoplasmosis with hemophagocytic lymphohistiocytosis and epithelioid cell granulomatosis: A case report and review of the literature. Eur J Haematol 2017; 99:91.</a></li><li><a class="nounderline abstract_t">Schwartz S, Cornely OA, Hamed K, et al. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Med Mycol 2020; 58:417.</a></li><li><a class="nounderline abstract_t">Hage CA, Connolly P, Horan D, et al. Investigation of the efficacy of micafungin in the treatment of histoplasmosis using two North American strains of Histoplasma capsulatum. Antimicrob Agents Chemother 2011; 55:4447.</a></li><li><a class="nounderline abstract_t">Hage CA, Kirsch EJ, Stump TE, et al. Histoplasma antigen clearance during treatment of histoplasmosis in patients with AIDS determined by a quantitative antigen enzyme immunoassay. Clin Vaccine Immunol 2011; 18:661.</a></li><li><a class="nounderline abstract_t">Tucker RM, Williams PL, Arathoon EG, et al. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother 1988; 32:369.</a></li><li><a class="nounderline abstract_t">Haynes RR, Connolly PA, Durkin MM, et al. Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. J Infect Dis 2002; 185:1830.</a></li><li><a class="nounderline abstract_t">de Gans J, Portegies P, Tiessens G, et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992; 6:185.</a></li><li><a class="nounderline abstract_t">Freifeld AG, Iwen PC, Lesiak BL, et al. Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center. Transpl Infect Dis 2005; 7:109.</a></li><li><a class="nounderline abstract_t">Reddy P, Gorelick DF, Brasher CA, Larsh H. Progressive disseminated histoplasmosis as seen in adults. Am J Med 1970; 48:629.</a></li><li><a class="nounderline abstract_t">Franklin AD, Larson L, Rauseo AM, et al. A comparison of presentations and outcomes of histoplasmosis across patients with varying immune status. Med Mycol 2021.</a></li><li><a class="nounderline abstract_t">Mata-Essayag S, Colella MT, Roselló A, et al. Histoplasmosis: a study of 158 cases in Venezuela, 2000-2005. Medicine (Baltimore) 2008; 87:193.</a></li></ol></div><div id="topicVersionRevision">Topic 2461 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16477560" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hospitalizations for endemic mycoses: a population-based national study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21539506" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epidemiology of endemic systemic fungal infections in Latin America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25420811" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Histoplasmosis in renal transplant patients in an endemic area at a reference hospital in Medellin, Colombia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7356773" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Disseminated histoplasmosis: clinical and pathologic correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17049017" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Improvements in diagnosis of histoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6312246" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2233233" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416614" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Disseminated histoplasmosis in AIDS: findings on chest radiographs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2197524" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Histoplasma capsulatum infections of the central nervous system. A clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28275076" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Laboratory Diagnostics for Histoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27875685" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Progressive disseminated histoplasmosis: a systematic review on the performance of non-culture-based diagnostic tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17223625" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Histoplasmosis: a clinical and laboratory update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11474016" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Evaluation of BACTEC MYCO/F Lytic medium for recovery of mycobacteria, fungi, and bacteria from blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7741115" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comparison of the BacT/Alert and Isolator blood culture systems for recovery of fungi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17505255" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Systemic histoplasmosis: a 15-year retrospective institutional review of 111 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25181311" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Histoplasma capsulatum endocarditis: multicenter case series with review of current diagnostic techniques and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25870331" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Histoplasmosis complicating tumor necrosis factor-αblocker therapy: a retrospective analysis of 98 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24046304" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Histoplasmosis after solid organ transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21810734" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A multicenter evaluation of tests for diagnosis of histoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26797210" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Improved Diagnosis of Acute Pulmonary Histoplasmosis by Combining Antigen and Antibody Detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19951231" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17913863" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Detection of histoplasma antigen by a quantitative enzyme immunoassay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19357311" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Development and evaluation of an enzyme-linked immunosorbent assay to detect Histoplasma capsulatum antigenuria in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17428951" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Production and evaluation of reagents for detection of Histoplasma capsulatum antigenuria by enzyme immunoassay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17580268" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Performance characteristics of a polyclonal enzyme immunoassay for the quantitation of Histoplasma antigen in human urine samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23966508" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Evaluation of an enzyme immunoassay for detection of Histoplasma capsulatum antigen from urine specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25631806" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Reevaluation of commercial reagents for detection of Histoplasma capsulatum antigen in urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26337088" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Evaluation of two new enzyme immunoassay reagents for diagnosis of histoplasmosis in a cohort of clinically characterized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9195077" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cross-reactivity in Histoplasma capsulatum variety capsulatum antigen assays of urine samples from patients with endemic mycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19837826" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diagnosis of histoplasmosis by antigen detection in BAL fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21752970" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Detection of Blastomyces dermatitidis and Histoplasma capsulatum from culture isolates and clinical specimens by use of real-time PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12517849" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Nested PCR assays for detection of Blastomyces dermatitidis DNA in paraffin-embedded canine tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26705837" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Detection of Histoplasma capsulatum from clinical specimens by cycling probe-based real-time PCR and nested real-time PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33706012" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Evaluation of a New Histoplasma spp. Quantitative RT-PCR Assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15736018" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Diagnosis and management of central nervous system histoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29595679" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Central nervous system histoplasmosis: Multicenter retrospective study on clinical features, diagnostic approach and outcome of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020213" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Improvement in Diagnosis of Histoplasma Meningitis by Combined Testing for Histoplasma Antigen and Immunoglobulin G and Immunoglobulin M Anti-Histoplasma Antibody in Cerebrospinal Fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26910223" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Application of the 1,3-β-D-Glucan (Fungitell) Assay in the Diagnosis of Invasive Fungal Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25540391" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : (1,3)-β-d-glucan in cerebrospinal fluid for diagnosis of fungal meningitis associated with contaminated methylprednisolone injections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24336827" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Utility of (1-3)-β-D-glucan testing for diagnostics and monitoring response to treatment during the multistate outbreak of fungal meningitis and other infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25378578" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Utility of measuring (1,3)-β-d-glucan in cerebrospinal fluid for diagnosis of fungal central nervous system infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27558179" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cerebrospinal Fluid (1,3)-Beta-d-Glucan Testing Is Useful in Diagnosis of Coccidioidal Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30021828" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Detection of (1,3)-β-d-Glucan in Cerebrospinal Fluid in Histoplasma Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30534945" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : An interferon gamma release assay specific for Histoplasma capsulatum to detect asymptomatic infected individuals: A proof of concept study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24890837" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mendelian genetics of human susceptibility to fungal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10620648" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical problem-solving. Impatient inpatient care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17806045" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of the midwestern endemic mycoses, histoplasmosis and blastomycosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11451696" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7709945" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1332471" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33070192" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Voriconazole Versus Itraconazole for the Initial and Step-down Treatment of Histoplasmosis: A Retrospective Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8922792" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Fluconazole therapy for histoplasmosis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27169478" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24589027" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12118965" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12118965" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33590676" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A novel highly bio-available itraconazole formulation (SUBA®-Itraconazole) for anti-fungal prophylaxis in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31360992" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical experience with new formulation SUBA®-itraconazole for prophylaxis in patients undergoing stem cell transplantation or treatment for haematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9316555" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11751146" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11692303" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16627592" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A case of cerebral histoplasmosis in an immunocompetent host successfully treated with voriconazole</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24371742" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : An instructive case of CNS histoplasmosis in an immunocompetent host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19139290" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Voriconazole use for endemic fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20796238" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Disseminated cutaneous histoplasmosis in an immunocompetent child, relapsed with itraconazole, successfully treated with voriconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18474746" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Successful treatment of histoplasmosis brain abscess with voriconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135526" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Activity of posaconazole in the treatment of central nervous system fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16824608" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Salvage treatment of histoplasmosis with posaconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16230202" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28349614" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Progressive histoplasmosis with hemophagocytic lymphohistiocytosis and epithelioid cell granulomatosis: A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31613363" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670186" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Investigation of the efficacy of micafungin in the treatment of histoplasmosis using two North American strains of Histoplasma capsulatum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21307278" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Histoplasma antigen clearance during treatment of histoplasmosis in patients with AIDS determined by a quantitative antigen enzyme immunoassay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2835002" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12085335" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1313682" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16390398" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5425240" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Progressive disseminated histoplasmosis as seen in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33443574" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A comparison of presentations and outcomes of histoplasmosis across patients with varying immune status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626302" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Histoplasmosis: a study of 158 cases in Venezuela, 2000-2005.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
